International Stem Cell Corporation’s (ISCO) subsidiary, Lifeline Cell Technology (Lifeline), contributed a critical role in developing a cell culture media that is suitable to grow the blood vessels used by Cytograft Tissue Engineering.
As seen in the American Heart Association ‘s innovative forum for late breaking science, “Emerging Science Series” webinar, Focus on Thrombosis and Vascular Biology, Cytograft’s technology has shown positive clinical results in the extensive market for vascular grafts; a market that exceeds 500,000 patients.
Applications for this technology include vascular shunts for hemodialysis for patients with kidney disease, lower limb circulation problems and coronary artery bypass grafts. If approved in further upcoming clinical trials, Lifeline’s media will be made to clinical grade in its cGMP media manufacturing facilities.
Coverage of this important story has been reported in the following media:
Forbes
CNN
